Join the Eosinophilic Esophagitis group to help and get support from people like you.
Eosinophilic Esophagitis News
Related terms: EE
Guidance Developed for Diagnosis, Management of Eosinophilic Esophagitis
FRIDAY, Jan. 24, 2025 – In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are...
Histologic Response Up With Benralizumab for Eosinophilic Esophagitis
WEDNESDAY, June 26, 2024 – Benralizumab yields a greater histologic response than placebo for patients with eosinophilic esophagitis, but does not affect dysphagia symptoms, according to a study...
Dupilumab Ups Histologic Response for Pediatric Eosinophilic Esophagitis
THURSDAY, June 27, 2024 – For children with eosinophilic esophagitis, dupilumab results in a significantly higher percentage of histologic remission, according to a study published in the June 27...
FDA Approves Eohilia (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
OSAKA, Japan and CAMBRIDGE, Massachusetts, February 12, 2024 – Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia (budesonide oral s...
Dupixent (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
TARRYTOWN, N.Y. and PARIS, Jan. 25, 2024 (GLOBE NEWSWIRE) – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Dupixent (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date Dupixent...